Pennsylvania vs New Jersey Cannabis Laws

Pennsylvania is the second-largest medical-only cannabis market in the United States, trailing only Florida. The state's Medical Marijuana Act was signed in April 2016, and dispensaries began serving patients in 2018. The market has grown to approximately $2 billion in annual sales, supported by a patient registry that has grown to over 400,000 active cardholders.

The Pennsylvania market operates under a limited license structure with vertically integrated grower/processor permits and separately issued dispensary licenses. The state has issued a limited number of each, making Pennsylvania licenses among the most valuable in the industry. Governor Josh Shapiro has publicly supported recreational legalization, and legislative efforts continue, making Pennsylvania one of the most watched states for potential recreational conversion.

Pennsylvania is a critical market for nearly every major MSO. Curaleaf, Green Thumb Industries, Trulieve, Cresco Labs, Verano, TerrAscend, and Ayr Wellness all hold licenses in the state. If recreational legalization passes, the market could potentially double or triple in size given the state's 13 million population. The current 5% gross receipts tax on grower/processors is relatively modest, with no additional patient-facing cannabis tax beyond standard considerations. Pennsylvania's potential recreational conversion is one of the most significant catalysts for the cannabis industry.

New Jersey has become one of the most important cannabis markets on the East Coast since launching recreational sales in April 2022. Voters overwhelmingly approved Public Question 1 in November 2020 with 67% support, and the state has attracted significant investment from nearly every major MSO. New Jersey's location at the heart of the New York metropolitan area — the largest metro area in the United States — gives it an outsized consumer base relative to its population of 9.3 million.

The New Jersey market has grown rapidly, surpassing $1.8 billion in annual revenue. The state benefited enormously from being the first in the immediate New York metro area to offer legal recreational sales, drawing consumers from New York City and surrounding areas. Even after New York's recreational program launched, New Jersey has maintained strong sales due to its more established retail infrastructure and competitive pricing.

Nearly all major MSOs have a presence in New Jersey, including Curaleaf, Green Thumb Industries, Trulieve, Cresco Labs, Verano, TerrAscend, Ayr Wellness, and Columbia Care. The state's relatively low tax rate of 6.625% (plus local transfer taxes) has been a competitive advantage. New Jersey is considered one of the premier cannabis markets in the country due to its population density, consumer demand, and favorable regulatory environment.